Selective Prostacyclin Receptor Agonist Selexipag, in Contrast to Prostacyclin Analogs, Does Not Evoke Paradoxical Vasoconstriction of the Rat Femoral Artery
Authors:
Open Access
- 1 June 2018
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 365 (3) , 727-733
Abstract
Selexipag [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide] is a selective nonprostanoid prostacyclin (PGI2) receptor (IP receptor) agonist that is approved for the treatment of pulmonary arterial hypertension (PAH). In contrast to selexipag, PGI2 analogs used in the clinic are nonselective agonists at prostanoid receptors and can also activate contractile prostaglandin E receptor 3 (EP3) receptors. Leg pain is a common side effect in patients receiving treatment with PGI2 analogs and peripheral vasoconstriction can be responsible for side effects related to muscular ischemia. This study tested the hypothesis that PGI2 analogs could cause paradoxical vasoconstriction of the femoral artery via EP3 receptor activation but that only vasorelaxation would be observed in response to selexipag and its active metabolite ACT-333679 [{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid]. Selexipag and ACT-333679 relaxed rings of the isolated rat femoral artery contracted with either prostaglandin F2α (PGF2α) or the α1 adrenoceptor (α1AR) agonist phenylephrine. ACT-333679 also inhibited contraction of the femoral artery to sympathetic nerve stimulation. In contrast, PGI2 analogs (iloprost, beraprost, and treprostinil) caused additional contraction of arterial rings precontracted with phenylephrine, which was reverted to relaxation by antagonism of EP3 receptors. Treprostinil augmented contraction of the femoral artery to sympathetic nerve stimulation in an EP3 receptor–dependent manner. Mechanistically, concomitant EP3 and α1AR receptor activation synergistically constricted femoral arteries. It is concluded that selexipag and ACT-333679 are vasorelaxants of the rat femoral artery and, unlike PGI2 analogs, do not cause paradoxical vasoconstriction via activation of EP3 receptors. EP3 receptor–mediated vasoconstriction may contribute to the well documented peripheral muscle pain reported in patients with PAH receiving PGI2 analogs. Leg pain may be less in patients treated with selexipag.Keywords
This publication has 31 references indexed in Scilit:
- Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor AntagonistThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Cardioprotective prostacyclin signaling in vascular smooth muscleProstaglandins & Other Lipid Mediators, 2007
- Investigation of the pronounced synergism between prostaglandin E2 and other constrictor agents on rat femoral arteryProstaglandins, Leukotrienes and Essential Fatty Acids, 2006
- Differential Effects of Selective Cyclooxygenase-2 Inhibitors on Endothelial Function in Salt-Induced HypertensionCirculation, 2003
- Structure–Activity Relationship of Biaryl Acylsulfonamide Analogues on the Human EP3 Prostanoid ReceptorBioorganic & Medicinal Chemistry Letters, 2002
- ABC of arterial and venous disease: Chronic lower limb ischaemiaBMJ, 2000
- The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogsBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2000
- An Imbalance between the Excretion of Thromboxane and Prostacyclin Metabolites in Pulmonary HypertensionNew England Journal of Medicine, 1992
- Vascular adrenergic neuroeffector function does not decline in aged rats.Circulation Research, 1985
- Effects of prostacyclin (PGI2), 6-oxo-PGF1 alpha and PGE2 on sympathetic nerve function in mesenteric arteries and veins of the rabbit in vitro.Hypertension, 1979